Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2502
    -0.0009 (-0.07%)
     

  • Bitcoin GBP

    51,194.34
    -450.40 (-0.87%)
     

  • CMC Crypto 200

    1,334.27
    -62.27 (-4.46%)
     

  • S&P 500

    5,106.28
    +57.86 (+1.15%)
     

  • DOW

    38,290.57
    +204.77 (+0.54%)
     

  • CRUDE OIL

    83.77
    +0.20 (+0.24%)
     

  • GOLD FUTURES

    2,351.80
    +9.30 (+0.40%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Denali Therapeutics Inc. (DNLI) Moves 17.7% Higher: Will This Strength Last?

Zacks Equity Research
·2-min read

Denali Therapeutics Inc. (DNLI) shares ended the last trading session 17.7% higher at $32.12. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 1.8% loss over the past four weeks.

Shares gained as investors are impressed by the company’s progress with its pipeline candidates.  Denali possesses a notable portfolio of targeted therapeutic candidates for neurodegenerative diseases which promise potential.

 

This company is expected to post quarterly loss of $0.83 per share in its upcoming report, which represents a year-over-year change of -20.3%. Revenues are expected to be $10.06 million, up 90.1% from the year-ago quarter.

ADVERTISEMENT

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For Denali Therapeutics Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on DNLI going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Denali Therapeutics Inc. belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Zymeworks Inc. (ZYME), closed the last trading session 1.3% higher at $5.58. Over the past month, ZYME has returned -14.2%.

Zymeworks Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.86. Compared to the company's year-ago EPS, this represents a change of +31.2%. Zymeworks Inc. currently boasts a Zacks Rank of #3 (Hold).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Denali Therapeutics Inc. (DNLI) : Free Stock Analysis Report
 
Zymeworks Inc. (ZYME) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research